EP-1266: Interstitial brachytherapy using MUPIT in locally advanced or recurrent gynecological malignancies  by Letelier, H. et al.
3rd ESTRO Forum 2015                                                                                                                                         S683 
 
evaluation and allows clearly define the contours of the 
tumor for planning brachytherapy.  
   
EP-1264   
Integrated EBRT dose escalation for pelvic lymph nodes 
positive uterine cervical carcinoma 
K. Akbarov1, I. Isayev1, E. Quliyev1, N. Aliyeva1 
1National Oncological Centre, Radiotherapy, Baku, 
Azerbaijan  
 
Purpose/Objective: Uterine cervical carcinoma is still 
remaining one of the main mortality reasons for female 
population in the developing world. Inspite of widely 
accessible screening and diagnostic procedures in the vast 
majority of cases in our country cervical cancer is revealed in 
locally advanced stages with metastasis in pelvic and 
paraaortal lymph nodes in up to 34% of patients. Concurrent 
chemoradiotherapy is the treatment of choice for cervical 
cancer today but the presence of positive lymph nodes 
require escalation of EBRT dose to these targets. The aim of 
this research was analysis of treatment results of 62 node 
positive cervical cancer patients. 
Materials and Methods: We used the method of integrated 
boost by volumetric arc therapy (VMAT) to increase the EBRT 
dose in target while keeping relatively low doses at the 
organs at risk (bowel, rectum, bladder, femoral heads, pelvic 
bones). Planning was done in automatic regimen and the dose 
distribution was better (more conformal) if two dynamic arcs 
with 15 MV photon beams were used. Number of fractions 
were 25. Fraction dose prescribed to the pelvis (primary 
tumor and regional zone) was 2.0 Gy while to the metastatic 
lymph nodes – 2.3 Gy at the same fraction what makes totally 
50 and 59 Gy respectively (EQD2 by α/β = 10). From the first 
day of treatment patients received concurrently weekly 
cisplatin in dose 40 mg/m2 (max. 70 mg), 5 infusions. After 46 
Gy of EBRT we started HDR brachytherapy which was 
consisted of two weekly 9.0 Gy fractions to HRCTV. 
Results: We analysed close results of the treatment which 
were assessed one month after the course completed. 
Complete regression, partial regression and stabilisation of 
the tumor developed in 83,9% (n=52), 11,3% (n=7), and 4,8% 
(n=3) cases respectively. Early hematological toxicity, 
enteritis, rectitis and cystitis of II – III stages observed in 
42,3%, 15,4%, 11,2% and in 4,3% cases accordingly. 
Conclusions: VMAT EBRT with integrated boost, HDR 
brachytherapy and concurrent cisplatin appears to be safe 
and effective treatment modality for pelvic lymph node 
metastatic uterine cervical carcinoma providing high rate 
local tumor control and acceptable early toxicity. But to do 
final conclusions we need longer follow up period. 
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Purpose/Objective: Treatment of locally advanced cervical 
cancer combines chemotherapy, EBRT and intracavity 
brachytherapy. Differing dose and fractionation schedules 
exist for the use of intracavity brachytherapy in cervical 
carcinoma. Following the switch from MDR to HDR in 2007, 
treatment within our centre was directed by ABS guidelines 
involving 30Gy in 5 fractions until 2010. From 2010 onwards 
due resource availability an altered schedule of 24Gy in 4 
fractions was implemented. We sought to analyse and 
compare outcomes for these two regimens. 
Materials and Methods: A retrospective analysis of treatment 
and outcomes was conducted for patients receiving primary 
chemo radiation for cervical carcinoma between Nov 2007 – 
Feb 2009 and Feb 2010 - Feb 2011. Overall survival and 
recurrence rates were analysed using Kaplan Meier survival 
analysis. Late toxicity was assessed according to 
RTOG/EORTC Late Morbidity Scoring Scheme. 
Results: 123 patients were identified. Patients received 
pelvic EBRT to a dose of 4500cGy in 25 fractions with a 
combination of platinum based induction or concomitant 
chemotherapy schedules followed by intracavity HDR 
brachytherapy. 59 patients received 3000cGy in 5 fractions 
(Group A) and 64 patients received 2400cGy in 4 fractions 
(Group B) of HDR intracavity brachytherapy. Patient 
characteristics were comparable between Group A and B, 
median age 48 (range 24 – 76) and 50 years (range 30 – 88) 
respectively. Squamous cell carcinoma was the most 
commonly observed histological subtype in both groups. Local 
control rates at 3 years are 75% and 81.6% for Group A and B 
respectively. Distant control at 3 years for Group A is 72.5% 
compared to 84.7% in Group B. There was no significant 
difference in PFS between Groups (log rank p = 0.16). OS at 3 
years in Group A was 58% compared to 73% in Group B (log 
rank p = 0.059). The rate of fistula development was 6.8% 
and 4.7% for Group A and B respectively. Late G3 /4 toxicity 
rates in Group A were reported as 10.2% compared with 
6.25% in Group B.  
Conclusions: A reduced dose fractionation schedule to 
2400cGy in 4 fractions is safely deliverable when compared to 
3000cGy in 5 fractions. There is no increase in recurrence or 
late toxicity seen in our patient group. It may be a preferable 
treatment delivery schedule resulting in reduced theatre 
time, reduced number of insertions and anaesthesia 
requirement.  
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Purpose/Objective: Martinez Universal Perineal Interstitial 
Template (MUPIT) is a device designed for the treatment of 
pelvic malignancies or recurrences via perineal. This 
technique allows treating locally advanced gynecological 
tumors, with a better dose coverage than conventional 
intracavitary therapy. Because of the complexity of this 
technique, it is only performed in experienced centers. There 
are few reports of their use in the literature, and with a little 
number of patients in each study. 
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The purpose of this study was to assess characteristics, 
treatment outcomes and complications in patients with 
locally advanced or recurrent gynecological malignancies 
treated with interstitial brachytherapy using MUPIT. 
Materials and Methods: We performed a retrospective 
review of all patients with gynecological malignancies 
treated with MUPIT in a single institution between January 
2005 and May 2014. Cases without data or follow up were 
excluded. Information recorded were demographic and clinic 
characteristics, previous use of RT (external or BT), dose rate 
of interstitial BT, local control rate, late toxicity and 
mortality rate. Categorical variables are presented as 
frequencies and proportions, and continuous variables as the 
mean, median, and range. Local recurrence-free survival 
(LRFS) and overall survival (OS) after MUPIT treatment were 
estimated using the Kaplan-Meier method. 
Results: Forty six patients were identified. The median age 
was 64 years (range, 28 - 85). Cervical and endometrial 
cancers were the most common primary site, with 20 and 16 
cases respectively. The indications of interstitial BT were 
treatment of local recurrence (31), primary tumor (14) and 
metastases (1). Forty patients received external RT or BT 
before interstitial BT. High dose rate BT was used in 37 cases. 
Median LRFS was 76.2 months (CI 95% 61.6 - 90.7) and the 
median survival time was 82 months (CI 95% 67.5 - 96.5). 
There have been no cases of Grade IV late toxicity. Proctitis 
and pelvic pain were the most common grade III 
complications (4 patients). 
Conclusions: Interstitial BT using MUPIT applicator is an 
effective treatment which obtains high rates of local control 
despite the bad prognosis of pelvic recurrencies. Secondary 
effects are few, and manageable. 
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Purpose/Objective: Bone marrow sparing using intensity-
modulated radiotherapy (IMRT) could reduce haematological 
toxicity from radical chemoradiation for cervical carcinoma. 
One challenge is to determine the location of functioning 
bone marrow rather than attempt to spare the whole bony 
pelvis. On FDG-PET the areas of higher activity correlate with 
SUV values, and the scans used to stage disease could 
potentially be used to also identify functioning bone marrow. 
The aims of this study were to identify functioning pelvic 
bone marrow using FDG-PET, to analyse the pattern of 
distribution between patients and to develop guidelines for 
defining bone marrow as an organ at risk which can be 
applied to radiotherapy CT scans for all patients.  
Materials and Methods: The FDG-PET scans from 10 patients 
treated for cervical cancer were assessed. Structure sets 
consisting 6 absolute SUV thresholds (0.5,1.0, 1.5, 2.0, 2.5 
and 3.0) were created. The distribution of SUV activity within 
each pelvic subregion and the whole bony pelvis was 
analysed. The maximum SUV value within the bony pelvis 
(SUVmax) was defined as the highest level with a volume > 
1cc. Volumetric data for SUVMax, SUV >75%Max (SUV75) and 
SUV>50%Max (SUV50) were compared, measuring the 
contribution to each region and to the total activity.  
Results: The absolute SUV values within the pelvis varied 
between patients whereas relative values were more 
comparable. A reproducible pattern of distribution was 
evident in all patients using SUV75. The highest activity is 
seen within the lumbar spine, sacrum, posterior iliac alae and 
pubic bone contributing 86.67% total activity. For SUV75, the 
SUV range was 1.0 – 2.5 with a mean volume of 98.9cc (Range 
19.99 – 196.0cc, SD 50.3), which is 6.9% (range 1.7 – 12.9, SD 
3.2) of the mean total pelvic volume. 
Conclusions: There is a reproducible pattern of functional 
bone marrow on FDG-PET within the pelvis. Guidelines for 
contouring a standard avoidance structure on the planning CT 
scan have been generated which encompass the areas of 
highest activity. Bone marrow avoidance should be assessed 
further in dosimetric and clinical studies. 
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Purpose/Objective: To monitor changes in tumour 
microenvironment including hypoxia of cervix cancer patients 
undergoing chemoradiation with positron emission 
tomography and multiparametric 3T-magnetic resonance 
imaging (MP-PET/MRI) using T2-weighted, T1-weighted, 
dynamic-contrast-enhanced (DCE) MRI, diffusion-weighted 
imaging (DWI) and 18F-fluoromisonidazole 
(18F-FMISO). 
Materials and Methods: Seven patients underwent 18F-FMISO-
PET/CT and MP-MRI at baseline; 2 and 5 weeks(w) after 
treatment start and 3 months after treatment end. Data were 
registered, fused and analyzed using Mirada RTx software 
(Mirada Medical Ltd, Oxford,UK). Gross tumour volume (GTV) 
was contoured by an experienced radiation oncologist on 
PET/MRI data sets. The volume of GTV was analysed for size, 
EH-kinetics, diffusivity and 18F-FMISO-avidity using SUVmax 
and SUV-normalized to gluteal muscle uptake. At follow up, 
cervix was contoured, since all patients showed clinically 
complete remission. 
Results: Median GTV volume was 43.9cc at baseline, 22.4cc 
after 2w (20-25Gy) and 7.7cc after 5w (40-45Gy). Mean ADC 
values were 1.02x10-3mm2/sec increasing to 1.18x10-
3mm2/sec after 2w and to 1.27x10-3mm2/sec after 5w and 
were 1.37x10-3mm2/sec at 3 months. All GTVs showed mean 
initial-enhancement (IE) followed by a plateau with an 
increasing IE at 2w and 5w and wash-out at 5w. At follow-up, 
the mean IE was 120% followed by a persistent enhancement. 
The mean 18F-FMISO SUV-norm was 3.1 at baseline and 
decreased to 2.3 at 2w and 2.0 at 5w and follow-up. 
Conclusions: There are morphological and functional changes 
in tumor diffusion, perfusion and hypoxia during treatment 
which can be non-invasively monitored with MP-MRI/PET. The 
